Advice on legislation or legal policy issues contained in this paper is provided for use in parliamentary debate and for related parliamentary purposes.
Today, drug delivery is experiencing a major expansion.
Recent progress in the field of molecular biology, biotechnology, and material sciences has resulted in the emergence of interesting technologies, which may hold great potential for the development of more efficient and safer pharmacological therapies. Paradoxically, the concomitant upsurge in published reports on drug-delivery systems does not correlate with therapeutic advances.
I know what he means. For some years now, the journals have prominently featured all sorts of highly engineered drug delivery systems — tissue-directed nanospheres and that sort of thing.
The work is conceptually quite interesting and seems to hold a lot of potential, but you know, it has been some years now since this stuff started to appear, and the number of these things that have made a dent in the real world is small.
Some of the assumptions behind these efforts may not hold up, either: Indeed, a large proportion of what is nowadays published, especially in chemistry and nonspecialized journals, relates to nanosized carriers nanoparticles, nanocapsules, drug—polymer conjugates, etc.
In such systems, the tumor-targeting principle generally relies on the enhanced permeation and retention EPR effect. And that stuff is perhaps not getting the detailed reviewing it should when it moves up in this fashion, which is a general problem in the literature.
You end up with a situation where the highest-profile publications end up as some of the less potentially reproducible ones, a situation that the chemists and biologists in the crowd will be familiar with.
Toxicity is just one of the issues that can get swept under the scientific rug under these conditions. Reproducibility is another thing that LeRoux highlights, and he makes the valid point that in a field as close to the clinic as drug formulation and delivery that it really should have higher standards than usual.
These are technologies that could have direct impact on human patients and volunteers, and some serious money will be spent in that regard. The field is not well served by the excuse that finicky details are hard to translate from one lab to another — this is an area, like process chemistry, that is supposed to be hammering those sorts of things out, not using them to rationalize trouble.
The whole point is generating robust work.The goal of the drug policy of creating a drug-free nation has therefore terribly failed to yield any fruit. The policies on the war drugs have always failed because, for one fact, the United States government has thought that an increase in the number of drug prisoners is an indicator of success in this war.
The National Drug Court Resource, Policy, and Evidence-Based Practices Center provides information and resources to the drug court field. The NDCRC is housed at the Justice Programs Office, a center within American University’s School of Public Affairs. With increasing utilization of robots in daily tasks, especially in biomedical and environmental monitoring applications, there would be demands for soft, biodegradable, or even edible actuators that provide more versatility than conventional rigid materials (e.g., metals and plastics).
Local Drug Court Research: Navigating Performance Measures and Process Evaluations Prepared by the National Drug Court Institute, the education, research, and scholarship affiliate of the National Association of Drug Court Professionals.
Marijuana is the common name given to any drug preparation from the hemp plant, Cannabis sativa. Various forms of this drug are known by different names throughout the world, such as kif in Morocco, dagga in South Africa, and ganja in India.
Cato’s education research is founded on the principle that parents are best suited to make important decisions regarding the care and education of their children.